BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Avita Medical Skin Regeneration Symposium Attracts Top European Surgeons


3/28/2013 9:17:14 AM

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwire - March 28, 2013) -

Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY)

  • Leading surgeons and clinicians attend from throughout Europe
  • Parallel presentation tracks covering burns, plastics, aesthetics and chronic wounds

Regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY), sponsored the second annual Skin Regeneration Symposium held in Munich, Germany, 21-22 March 2013. The symposium provided a unique opportunity for expert users of ReCell® Spray-On Skin® to share their clinical research and experience in skin regeneration with other ReCell users.

A multi-disciplinary group of 37 ReCell experts, representing surgeons from Australia, France, Germany, Italy, the Netherlands, the United Kingdom, Turkey and the Czech Republic, met together with Company leaders to advise on clinical best practices, clinical trials and product enhancement.

The Symposium was organised as two parallel sessions chaired by Mr Jeremy Rawlins (AUS) and Dr Mohamed Al Abadie (UK). Seventeen papers were presented covering application of ReCell in the areas of Burn treatment, Plastic and Aesthetic applications (including the treatment of scars, dyspigmentation, vitiligo, and facial rejuvenation) and Chronic wounds (including treatment of venous and diabetic foot ulcers and other chronic/challenging wounds).

Keynote presentations were delivered by Professor Fiona Wood from Australia (Cell based therapies: The science and future potential) and Mr Andrew Quick, Avita's VP of Research and Technology (Cells make sense: Regenerative wound healing).

"The symposium was extremely well received by the participating surgeons," said Ms Debra Leeves, General Manager Avita Medical, Europe, Middle East and Africa. "By gathering together many of the key European ReCell surgeons this conference has fostered the open exchange of clinical results and sharing of best practises in the use of ReCell. Surgeons are looking forward to Avita's annual Regenerative Skin Symposium which will encourage and accelerate the continued uptake and incorporation of ReCell as the clinical standard of care in the treatment of a wide range of indications."

ABOUT AVITA MEDICAL LTD.
Avita Medical (http://www.avitamedical.com) develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is on market and generating early revenues. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.


Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES